{"id":1337,"date":"2018-01-02T11:29:22","date_gmt":"2018-01-02T16:29:22","guid":{"rendered":"https:\/\/health.uconn.edu\/cancer-dev\/?page_id=1337"},"modified":"2024-12-23T11:18:21","modified_gmt":"2024-12-23T16:18:21","slug":"research","status":"publish","type":"page","link":"https:\/\/health.uconn.edu\/cancer\/research\/","title":{"rendered":"Research"},"content":{"rendered":"\n

\n\t\tResearch\n\t<\/h1>\n\t\t\t\t\tBone Neoplasia Program<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Bone Neoplasia refers to abnormal bone growth, and this can sometimes include tumors located in the bone tissue. This program’s primary goal is to understand the formation of primary and secondary tumors that develop in the bones.<\/p>\n

Bone is a storage source of cytokines (proteins used for cell signaling) which are critical to tumor production. Because of this, bone is an important site of metastasis for breast and prostate as well as other types of cancer. The development of a primary bone tumor appears to be caused by the deregulation of the normal bone development process. A better understanding of the normal processes that take place during bone remodeling, when old bone tissue is reabsorbed, and new bone tissue is created, will improve our understanding of these same processes that are unregulated during both primary and secondary tumor development.<\/p>\n

Chaired by\u00a0Marc Hansen, Ph.D.<\/a>,\u00a0this group is comprised of faculty from multiple disciplines and interacts with the Musculoskeletal Signature Program.<\/p>\n\t\t\t\t\tCancer Control and Prevention <\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

This program was created in 2013. It consists primarily of smoking cessation\/reduction and pregnancy, a Colon Cancer Prevention Program, Cancer epidemiology (particularly breast and colorectal cancers), a breast imaging study, and a lung cancer screening program.<\/p>\n

The smoking cessation area is an academically solid, NIH-funded program of long standing, but is not necessarily tied to cancer.<\/p>\n

The Colon Cancer prevention area is a multi-disciplinary translational effort founded by Drs. Daniel Rosenberg and Joel Levine >10 years ago. This NIH-funded program is unique regionally and is among the very few such nationally integrated research-clinical programs. Its program objectives are:<\/p>\n

    \n
  1. To create large cohorts of patients at risk for colon cancer, integrating basic and applied science into long-term clinical risk reduction<\/li>\n
  2. To establish, by longitudinal follow-up of patients, data sets for the analysis of risk factors and interventions to prevent colon cancer<\/li>\n
  3. To encourage CCPP patients to participate in investigator-initiated basic science projects<\/li>\n
  4. To develop new approaches to population-based colon cancer risk assessment and reduction<\/li>\n<\/ol>\n

    Its program status by objective can be summarized thus:<\/strong><\/p>\n